Table S5. Results of DAVID pathway analysis on predicted targets of spatial specific miRNAs expressed in the ventral striatum. For each KEGG pathway the table shows the number of genes predicted, the fold enrichment relative to the genome, the p-value (modified Fisher exact test), the official symbol of predicted targets and miRNAs that could potentially target them. Pathways enriched in both brain regions are in blue, VS enriched pathways are indicated in grey. Green bold are miR-24 predicted targets.

KEGG pathway / Nr of genes / Fold enrichment / p-value / Genes / miRNAs
Axon guidance / 25 / 2.6 / 0.00002 / EFNA1, EPHA7, EPHA8, FYN, GSK3B, ITGB1, LIMK2, LRRC4C, NFAT5, NRAS, NTN3, PAK4, PAK6, PLXNA3, PPP3R1, RASA1, RHOA, ROCK1, SEMA4A, SEMA4B, SEMA4C, SEMA4G, SEMA5A, SEMA6A, SRGAP2 / 24, 92b, 136, 335-5p, 350, 710, 770-3p
Focal adhesion / 32 / 2.2 / 0.00004 / ARHGAP5, BIRC2, BRAF, COL11A1, COL1A2, COL5A1, COL5A2, CRKL, EGFR, FYN, GSK3B, IBSP, ITGA5, ITGA8, ITGB1, ITGB3, LAMA1, MAPK9, PAK4, PAK6, PDGFRA, PGF, PIK3CB, PIK3R3, PPP1CA, RAF1, RAP1A, RAP1B, RHOA, ROCK1, VAV1, XIAP / 24, 92b, 136, 335-5p, 350, 710
MAPK signaling pathway / 37 / 1.9 / 0.00018 / ACVR1B, ACVR1C, BDNF, BRAF, CACNA1G, CACNB4, CRKL, DUSP10, DUSP16, DUSP7, DUSP8, DUSP9, EGFR, ELK4, IL1R1, MAP2K4, MAP3K2, MAPK11, MAPK14, MAPK7, MAPK9, MAX, NLK, NRAS, PDGFRA, PLA2G4E, PPP3R1, PRKACB, RAF1, RAP1A, RAP1B, RASA1, RASGRP1, STK4, STMN1, TAB2, TAOK1 / 24, 92b, 136, 335-5p, 350, 710
Adherens junction / 15 / 2.7 / 0.00100 / ACVR1B, ACVR1C, EGFR, FYN, IQGAP1, NLK, PTPRF, PTPRM, RHOA, TCF7, TCF7L2, TJP1, WASF1, WASL, YES1 / 24, 92b, 136, 335-5p, 350, 710
Wnt signaling pathway / 23 / 2.1 / 0.00110 / BTRC, CAMK2B, CSNK1A1, CTBP1, CTNNBIP1, DAAM1, DKK2, FZD2, FZD5, GSK3B, MAPK9, NFAT5, NKD2, NLK, PPP2R1B, PPP3R1, PRKACB, RHOA, ROCK1, TBL1XR1, TCF7, TCF7L2, WNT8B / 24, 136, 335-5p, 350, 710
Neurotrophin signaling pathway / 20 / 2.1 / 0.00260 / BDNF, BRAF, CAMK2B, CRKL, FRS2, GSK3B, IRAK2, MAGED1, MAPK11, MAPK14, MAPK7, MAPK9, NRAS, PIK3CB, PIK3R3, RAF1, RAP1A, RAP1B, RHOA, YWHAB / 24, 92b, 136, 335-5p, 350, 710
ErbB signaling pathway / 15 / 2.4 / 0.00390 / BRAF, CAMK2B, CBL, CDKN1B, CRKL, EGFR, GSK3B, MAP2K4, MAPK9, NRAS, PAK4, PAK6, PIK3CB, PIK3R3, RAF1 / 24, 92b, 136, 335-5p, 350, 710
Long-term potentiation / 13 / 2.5 / 0.00430 / ADCY1, BRAF, CAMK2B, GRIA1, GRIN1, GRM5, NRAS, PPP1CA, PPP3R1, PRKACB, RAF1, RAP1A, RAP1B / 24, 92b, 136, 335-5p, 350, 710, 770-3p
Gap junction / 14 / 2.2 / 0.00900 / ADCY1, ADCY2, ADCY7, DRD1A, EGFR, GRM5, HTR2C, MAP3K2, MAPK7, NRAS, PDGFRA, PRKACB, RAF1, TJP1 / 24, 136, 335-5p, 350, 710
GnRH signaling pathway / 15 / 2.1 / 0.01000 / ADCY1, ADCY2, ADCY7, CAMK2B, EGFR, MAP2K4, MAP3K2, MAPK11, MAPK14, MAPK7, MAPK9, NRAS, PLA2G4E, PRKACB, RAF1 / 24, 92b, 136, 335-5p, 350, 710
Regulation of actin cytoskeleton / 24 / 1.5 / 0.04400 / ARPC2, BRAF, CHRM1, CRKL, EGFR, IQGAP1, ITGA5, ITGA8, ITGB1, ITGB3, LIMK2, NRAS, PAK4, PAK6, PDGFRA, PIK3CB, PIK3R3, PPP1CA, RAF1, RHOA, ROCK1, VAV1, WASF1, WASL / 24, 92b, 136, 335-5p, 350, 710
Apoptosis / 12 / 1.9 / 0.05100 / BCL2L1, BIRC2, CASP7, CSF2RB, IL1R1, IL1RAP, IRAK2, PIK3CB, PIK3R3, PPP3R1, PRKACB, XIAP / 24, 92b, 136, 335-5p, 350, 710
Amyotrophic lateral sclerosis (ALS) / 9 / 2.2 / 0.05300 / ALS2, BCL2L1, GRIA1, GRIN1, MAPK11, MAPK14, NEFH, NEFM, PPP3R1 / 24, 92b, 136, 335-5p, 350, 770-3p